Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
EXEL Exelixis, Inc. daily Stock Chart
EXEL [NASD]
Exelixis, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E10.98 EPS (ttm)1.96 Insider Own0.80% Shs Outstand296.24M Perf Week6.87%
Market Cap6.36B Forward P/E29.75 EPS next Y0.72 Insider Trans-22.95% Shs Float294.35M Perf Month8.70%
Income612.40M PEG0.24 EPS next Q0.17 Inst Own80.30% Short Float5.48% Perf Quarter32.35%
Sales956.10M P/S6.66 EPS this Y346.30% Inst Trans0.91% Short Ratio4.96 Perf Half Y-1.29%
Book/sh5.29 P/B4.06 EPS next Y-25.26% ROA38.30% Target Price25.00 Perf Year1.13%
Cash/sh2.57 P/C8.36 EPS next 5Y46.00% ROE42.50% 52W Range15.02 - 25.31 Perf YTD21.91%
Dividend- P/FCF13.68 EPS past 5Y29.60% ROI52.60% 52W High-15.84% Beta1.65
Dividend %- Quick Ratio6.80 Sales past 5Y93.70% Gross Margin96.90% 52W Low41.81% ATR0.80
Employees484 Current Ratio6.90 Sales Q/Q20.50% Oper. Margin42.20% RSI (14)67.81 Volatility4.19% 3.99%
OptionableYes Debt/Eq0.00 EPS Q/Q-23.80% Profit Margin64.00% Rel Volume0.48 Prev Close21.48
ShortableYes LT Debt/Eq0.00 EarningsFeb 25 AMC Payout0.00% Avg Volume3.25M Price21.30
Recom2.00 SMA2011.88% SMA5013.99% SMA20012.32% Volume909,520 Change-0.84%
Jan-13-20Initiated SunTrust Buy $31
Nov-13-19Initiated BofA/Merrill Buy $22
Mar-18-19Upgrade Morgan Stanley Underweight → Equal-Weight
Sep-17-18Initiated Goldman Neutral $22
Sep-10-18Initiated Morgan Stanley Underweight $19
May-11-18Reiterated Needham Buy $33 → $30
Oct-17-17Reiterated RBC Capital Mkts Outperform $33 → $39
Oct-17-17Reiterated Needham Buy $30 → $33
Oct-16-17Reiterated SunTrust Buy $32 → $35
Sep-22-17Downgrade Leerink Partners Outperform → Mkt Perform
Sep-15-17Initiated RBC Capital Mkts Outperform $32
Sep-12-17Reiterated Needham Buy $28 → $30
Jul-14-17Initiated SunTrust Buy $33
Mar-31-17Initiated Needham Buy $28
Mar-16-17Initiated Oppenheimer Perform
Feb-28-17Downgrade Stifel Buy → Hold $21 → $22
Nov-03-16Initiated Deutsche Bank Buy $17
Oct-10-16Upgrade Piper Jaffray Neutral → Overweight
Sep-15-16Reiterated Stifel Buy $12 → $15
Aug-04-16Reiterated Stifel Buy $10 → $12
Feb-21-20 11:30AM  Exelixis (EXEL) to Report Q4 Earnings: What's in the Cards? Zacks
Feb-19-20 07:28AM  The Exelixis (NASDAQ:EXEL) Share Price Has Soared 689%, Delighting Many Shareholders Simply Wall St.
Feb-12-20 04:05PM  Exelixis to Release Fourth Quarter and Full Year 2019 Financial Results on Tuesday, February 25, 2020 Business Wire
02:10PM  3 Mid-Cap Growth Stocks to Buy InvestorPlace
Feb-11-20 05:50PM  Exelixis (EXEL) Outpaces Stock Market Gains: What You Should Know Zacks
07:23AM  The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology Benzinga
Feb-10-20 05:00PM  Exelixis Announces Encouraging Results for Cabozantinib in Combination With Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Business Wire
Feb-04-20 05:50PM  Exelixis (EXEL) Gains But Lags Market: What You Should Know Zacks
Jan-29-20 08:30AM  The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut Benzinga
02:01AM  Exelixis Announces Partner Takeda Files New Drug Application in Japan for CABOMETYX® (cabozantinib) for Advanced Hepatocellular Carcinoma Business Wire
Jan-28-20 09:52AM  How Alameda again became a biotech hotspot American City Business Journals
Jan-27-20 08:07AM  Roche Submits Application for Tecentriq-Avastin Combo in HCC Zacks
Jan-24-20 07:30AM  Exelixis Announces Results for Combination of Cabozantinib and Nivolumab With or Without Ipilimumab in Advanced Hepatocellular Carcinoma Business Wire -7.92%
Jan-21-20 06:10PM  How this East Bay biotech went from debt to expansion American City Business Journals
Jan-17-20 11:40AM  GILD or EXEL: Which Is the Better Value Stock Right Now? Zacks
Jan-14-20 07:38AM  Does Exelixis, Inc. (NASDAQ:EXEL) Have A Good P/E Ratio? Simply Wall St. +6.39%
Jan-13-20 12:10PM  Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? Zacks
Jan-12-20 04:00PM  Exelixis Outlines Key Priorities and Anticipated Milestones for 2020-21, Announces Preliminary Fourth Quarter and Full Year 2019 Financial Results, and Provides 2020 Financial Guidance Business Wire
Jan-09-20 04:39PM  2019 Review: Top Hedge Fund Stocks vs. Exelixis, Inc. (EXEL) Insider Monkey
Jan-08-20 10:13AM  Exelixis to Expand Prostate Cancer Cohort of Cabometyx Study Zacks
10:07AM  Biotech Stock Roundup: Updates From INCY & EXEL, APLS & LIFE Surge on Positive Data Zacks
Jan-07-20 04:05PM  Exelixis to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020 Business Wire +6.38%
07:30AM  Exelixis Further Expands Prostate Cancer Cohort in Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Atezolizumab in Patients with Advanced Solid Tumors Business Wire
Dec-19-19 07:00AM  Exelixis Enters into a Clinical Collaboration for Three Phase 3 Combination Trials for Patients with Advanced Solid Tumors Business Wire
Dec-13-19 08:22AM  Roche's (RHHBY) Tecentriq Combo Succeeds in Melanoma Study Zacks
08:10AM  The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer Benzinga
01:02AM  Exelixis Announces Positive Results From IMspire150, the Phase 3 Trial of Atezolizumab Plus Cotellic and Vemurafenib in People With Previously Untreated BRAF V600 Mutation-Positive Advanced Melanoma Business Wire
Dec-06-19 01:03PM  Hedge Funds Are Warming Up To Exelixis, Inc. (EXEL) Insider Monkey
Dec-05-19 04:56AM  How Should Investors React To Exelixis, Inc.'s (NASDAQ:EXEL) CEO Pay? Simply Wall St.
Nov-26-19 04:06PM  Exelixis Announces Webcasts of Investor Conference Presentations in December Business Wire
12:20PM  Why Did Farallon Capital Get Out of These 3 Biotech Stocks? TipRanks
Nov-12-19 04:05PM  Exelixis to Present at the Stifel 2019 Healthcare Conference on November 19, 2019 Business Wire
08:02AM  Exelixis Partner Ipsen Announces Health Canadas Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Patients With Previously Treated Advanced Hepatocellular Carcinoma Business Wire
Nov-07-19 08:01PM  Exelixis Collaborator Daiichi Sankyo Announces Positive Results From Phase 3 Pivotal Trial of Esaxerenone in Patients With Diabetic Nephropathy Business Wire
Nov-05-19 03:36AM  Edited Transcript of EXEL earnings conference call or presentation 30-Oct-19 9:00pm GMT Thomson Reuters StreetEvents
Oct-31-19 11:45AM  Exelixis (EXEL) Q3 Earnings Beat on Strong Cabometyx Sales Zacks -11.10%
Oct-30-19 06:45PM  Exelixis (EXEL) Q3 Earnings and Revenues Beat Estimates Zacks
04:05PM  Exelixis Announces Third Quarter 2019 Financial Results and Provides Corporate Update Business Wire
08:00AM  Is There An Opportunity With Exelixis, Inc.'s (NASDAQ:EXEL) 31% Undervaluation? Simply Wall St.
Oct-29-19 10:40AM  Exelixis (EXEL) to Report Q3 Earnings: What's in the Cards? Zacks
Oct-25-19 10:15AM  Is Exelixis, Inc. (EXEL) Going To Burn These Hedge Funds ? Insider Monkey
Oct-23-19 10:33AM  Earnings Preview: Exelixis (EXEL) Q3 Earnings Expected to Decline Zacks
Oct-16-19 04:05PM  Exelixis to Release Third Quarter 2019 Financial Results on Wednesday, October 30, 2019 Business Wire
Oct-14-19 12:08PM  7 Under-The-Radar Growth Stocks That Could Benefit New Investors InvestorPlace
Oct-07-19 11:58AM  What Kind Of Shareholders Own Exelixis, Inc. (NASDAQ:EXEL)? Simply Wall St.
09:54AM  Calithera (CALA) Completes Enrollment in Mid-Stage RCC Study Zacks
Oct-01-19 11:45AM  Seattle Genetics Up on Positive Data From Bladder Cancer Study Zacks
Sep-25-19 04:05PM  Exelixis to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019 Business Wire
Sep-23-19 10:27AM  Pfizer's Bavencio Gets CHMP Recommendation for First-Line RCC Zacks
Sep-20-19 05:48PM  3 Pharmaceutical Companies to Consider as Lawmakers Continue to Fight for Lower Drug Prices GuruFocus.com
Sep-16-19 08:20AM  Have Insiders Been Selling Exelixis, Inc. (NASDAQ:EXEL) Shares? Simply Wall St.
Sep-13-19 09:36AM  Renal Cell Carcinoma Space in Focus: Some Key Developments Zacks
Sep-04-19 10:17AM  Biotech vet George Scangos steers new company toward nine-figure IPO American City Business Journals
Sep-03-19 04:05PM  Exelixis to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 Business Wire
Aug-26-19 08:04AM  These Fundamentals Make Exelixis, Inc. (NASDAQ:EXEL) Truly Worth Looking At Simply Wall St.
Aug-21-19 12:55PM  10 Small-Cap, Up-And-Coming Stocks to Keep on Your Radar InvestorPlace
Aug-20-19 11:15PM  Exelixis Inc (EXEL) EVP and General Counsel Jeffrey Hessekiel Sold $1.6 million of Shares GuruFocus.com
10:09AM  Exelixis (EXEL) Stock Up 15.2% YTD on Strong Cabometyx Sales Zacks
Aug-16-19 09:15PM  Exelixis Inc (EXEL) President and CEO Michael Morrissey Sold $704,654 of Shares GuruFocus.com +8.93%
Aug-05-19 11:46PM  Edited Transcript of EXEL earnings conference call or presentation 31-Jul-19 9:00pm GMT Thomson Reuters StreetEvents
10:00AM  Exelixis Hits Blockbuster Status Motley Fool
07:49AM  Is Exelixis, Inc. (NASDAQ:EXEL) A High Quality Stock To Own? Simply Wall St.
Aug-02-19 11:15PM  Exelixis Inc (EXEL) President and CEO Michael Morrissey Sold $709,560 of Shares GuruFocus.com
Aug-01-19 10:50AM  Exelixis (EXEL) Q2 Earnings & Sales Beat, Cabometyx Shines Zacks
07:18AM  The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings Benzinga
Jul-31-19 11:24PM  Exelixis Inc (EXEL) Q2 2019 Earnings Call Transcript Motley Fool
07:15PM  Exelixis (EXEL) Q2 Earnings and Revenues Beat Estimates Zacks
04:06PM  Exelixis Announces Second Quarter 2019 Financial Results and Provides Corporate Update Business Wire
04:05PM  Exelixis and Aurigene Enter Into Exclusive Collaboration, Option and License Agreement to Discover and Develop Novel Therapies for Cancer Business Wire
07:06AM  The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster Benzinga
Jul-26-19 03:17PM  Exelixis (EXEL) to Report Q2 Earnings: What's in the Cards? Zacks
09:18AM  3 Cancer Treatment Stocks to Buy Right Now Motley Fool
Jul-24-19 10:32AM  Exelixis (EXEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release Zacks
Jul-22-19 10:10AM  Can Exelixis (EXEL) Keep the Earnings Surprise Streak Alive? Zacks
Jul-19-19 11:15PM  Exelixis Inc (EXEL) President and CEO Michael Morrissey Sold $741,988 of Shares GuruFocus.com
Jul-18-19 11:45AM  Exelixis (NASDAQ:EXEL) Shareholders Have Enjoyed A Whopping 474% Share Price Gain Simply Wall St.
09:30AM  EXEL or ILMN: Which Is the Better Value Stock Right Now? Zacks
Jul-17-19 04:05PM  Exelixis to Release Second Quarter 2019 Financial Results on Wednesday, July 31, 2019 Business Wire
10:06AM  Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study Zacks
09:20AM  New Strong Buy Stocks for July 17th Zacks
Jul-16-19 01:15PM  Exelixis Adds & Expands Cohorts in Cabometyx-Tecentriq Study Zacks
Jul-15-19 07:00AM  Exelixis Updates Phase 1b COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Patients With Advanced Solid Tumors Business Wire
Jul-04-19 12:15AM  Exelixis Inc (EXEL) President and CEO Michael Morrissey Sold $730,183 of Shares GuruFocus.com
Jun-30-19 09:15AM  Is Exelixis a Buy? Motley Fool
Jun-29-19 06:00AM  3 Cancer-Treatment Stocks to Buy Motley Fool
Jun-24-19 09:59AM  Health Care Digest: How California's stem cell institute may help find glaucoma cure; a stealthy biotech with $100M; and more American City Business Journals
09:43AM  Read This Before You Buy Any New Cancer Drug Stocks Motley Fool
Jun-21-19 03:12PM  Oh, By the Way, This Clinical Trial Didn't Work Motley Fool
07:43AM  Dow Jones Futures: Canopy Growth, PayPal, Lululemon, Exelixis Active Investor's Business Daily
07:18AM  The Daily Biotech Pulse: ContraVir's Volatile Ride Continues, Late-Stage Disappointment For Exelixis, Regeneron-Sanofi Breathe Easy Benzinga
Jun-20-19 01:33PM  Heres What Hedge Funds Think About Exelixis, Inc. (EXEL) Insider Monkey
Jun-19-19 10:02AM  2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land TheStreet.com
Jun-07-19 06:00AM  Exelixis Bets on Breakthroughs in Oncology MoneyShow
Jun-06-19 01:55PM  Top 5 Stocks in the Fight Against Cancer Motley Fool
May-31-19 09:31AM  Why Is Exelixis (EXEL) Down 1% Since Last Earnings Report? Zacks
May-30-19 03:09PM  Is Exelixis, Inc.'s (NASDAQ:EXEL) CEO Being Overpaid? Simply Wall St.
May-29-19 04:05PM  Exelixis Announces Webcasts of Investor Conference Presentations in June 2019 Business Wire
May-24-19 08:25AM  Dow 30 Stock Roundup: Home Depot Earnings Impress, Merck to Buy Peloton Therapeutics Zacks
May-22-19 09:37AM  Merck to Buy Private Cancer Drugmaker Peloton Therapeutics Zacks
May-16-19 08:00AM  Exelixis and Iconic Therapeutics Enter into Exclusive Option and License Agreement for Novel Antibody-Drug Conjugate Program Business Wire
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. Exelixis, Inc. has collaboration and license agreement with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Merck, Invenra, Inc., StemSynergy Therapeutics, Inc., and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Garber Alan MDirectorFeb 14Sale21.0212,500262,75048,829Feb 14 08:36 PM
MORRISSEY MICHAELPresident and CEOFeb 13Option Exercise5.5125,000137,750110,985Feb 14 08:48 PM
MORRISSEY MICHAELPresident and CEOFeb 13Sale20.1125,000502,75085,985Feb 14 08:48 PM
SCANGOS GEORGE ADirectorFeb 12Sale20.0221,000420,4201,013,031Feb 12 08:21 PM
SCANGOS GEORGE ADirectorFeb 11Sale20.144,00080,5601,034,031Feb 12 08:21 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOFeb 07Option Exercise5.5150,000275,500375,122Feb 07 08:43 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOFeb 07Sale18.3750,000918,500325,122Feb 07 08:43 PM
MORRISSEY MICHAELPresident and CEOJan 29Option Exercise5.5125,000137,750110,985Jan 31 08:03 PM
MORRISSEY MICHAELPresident and CEOJan 29Sale17.8725,000446,75085,985Jan 31 08:03 PM
MORRISSEY MICHAELPresident and CEOJan 23Option Exercise5.5125,000137,750110,985Jan 24 08:19 PM
MORRISSEY MICHAELPresident and CEOJan 23Sale19.4125,000485,25085,985Jan 24 08:19 PM
SCANGOS GEORGE ADirectorJan 22Sale19.7525,000493,7501,038,031Jan 24 08:17 PM
MORRISSEY MICHAELPresident and CEOJan 16Option Exercise5.5125,000137,750110,985Jan 17 08:45 PM
MORRISSEY MICHAELPresident and CEOJan 16Sale20.3325,000508,25085,985Jan 17 08:45 PM
MARCHESI VINCENT TDirectorJan 15Sale20.0161,6831,234,27782,484Jan 17 08:50 PM
SCANGOS GEORGE ADirectorJan 15Sale20.3925,000509,7501,063,031Jan 17 08:42 PM
MORRISSEY MICHAELPresident and CEOJan 08Option Exercise5.5125,000137,750110,985Jan 09 08:35 PM
MORRISSEY MICHAELPresident and CEOJan 08Sale18.8525,000471,25085,985Jan 09 08:35 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOJan 07Option Exercise5.5150,000275,500375,122Jan 09 08:27 PM
Garber Alan MDirectorJan 07Option Exercise5.3986,956468,884148,285Jan 09 08:31 PM
Garber Alan MDirectorJan 07Sale18.0186,9561,566,07861,329Jan 09 08:31 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOJan 07Sale17.9650,000898,000325,122Jan 09 08:27 PM
MORRISSEY MICHAELPresident and CEOJan 02Option Exercise5.5125,000137,750110,985Jan 03 07:46 PM
MORRISSEY MICHAELPresident and CEOJan 02Sale17.4925,000437,25085,985Jan 03 07:46 PM
SCANGOS GEORGE ADirectorDec 27Sale18.2525,000456,2501,090,531Dec 27 08:52 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMODec 03Option Exercise5.5150,000275,500363,557Dec 05 08:11 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMODec 03Sale16.2250,000811,000313,557Dec 05 08:11 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMONov 04Option Exercise5.5150,000275,500374,331Nov 06 07:55 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMONov 04Sale15.9950,000799,500324,331Nov 06 07:55 PM
Haley Patrick J.Sr. Vice President, CommercialOct 10Sale16.273034,93089,209Oct 11 08:20 PM
MORRISSEY MICHAELPresident and CEOOct 02Option Exercise7.1835,409254,237231,513Oct 04 08:02 PM
MORRISSEY MICHAELPresident and CEOOct 02Sale17.6626,364465,588205,149Oct 04 08:02 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOOct 01Option Exercise5.5130,000165,300354,331Oct 03 09:03 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOOct 01Sale17.8730,000536,100324,331Oct 03 09:03 PM
MORRISSEY MICHAELPresident and CEOSep 18Option Exercise7.1850,000359,000233,331Sep 20 08:05 PM
MORRISSEY MICHAELPresident and CEOSep 18Sale19.2037,227714,758196,104Sep 20 08:05 PM
Haley Patrick J.Sr. Vice President, CommercialSep 10Sale18.841,00018,84085,453Sep 12 08:07 PM
POSTE GEORGEDirectorAug 16Option Exercise4.5825,000114,500137,792Aug 19 08:18 PM
Hessekiel JeffreyEVP and General CounselAug 16Option Exercise1.7075,000127,500308,820Aug 20 08:39 PM
Hessekiel JeffreyEVP and General CounselAug 16Sale21.1075,0001,582,500233,820Aug 20 08:39 PM
POSTE GEORGEDirectorAug 16Sale20.5025,000512,500112,792Aug 19 08:18 PM
MORRISSEY MICHAELPresident and CEOAug 14Option Exercise7.1850,000359,000200,109Aug 16 08:02 PM
MORRISSEY MICHAELPresident and CEOAug 14Sale20.1135,040704,654165,069Aug 16 08:02 PM
Haley Patrick J.Sr. Vice President, CommercialAug 12Sale20.391,00020,39086,453Aug 14 08:00 PM
POSTE GEORGEDirectorAug 09Option Exercise5.5920,000111,700132,792Aug 09 07:55 PM
POSTE GEORGEDirectorAug 09Sale20.6020,000412,000112,792Aug 09 07:55 PM
Haley Patrick J.Sr. Vice President, CommercialAug 06Option Exercise1.7025,00042,500112,453Aug 08 08:13 PM
Haley Patrick J.Sr. Vice President, CommercialAug 06Sale20.0225,000500,50087,453Aug 08 08:13 PM
MORRISSEY MICHAELPresident and CEOAug 02Option Exercise7.1850,000359,000185,149Aug 02 08:29 PM
MORRISSEY MICHAELPresident and CEOAug 02Sale20.2535,040709,560150,109Aug 02 08:29 PM
SCANGOS GEORGE ADirectorAug 01Sale20.5940,000823,7381,128,031Aug 02 08:27 PM
MORRISSEY MICHAELPresident and CEOJul 17Option Exercise7.1850,000359,000169,870Jul 19 08:04 PM
MORRISSEY MICHAELPresident and CEOJul 17Sale21.3734,721741,988135,149Jul 19 08:04 PM
Haley Patrick J.Sr. Vice President, CommercialJul 10Sale20.961,00020,96087,453Jul 12 07:53 PM
MORRISSEY MICHAELPresident and CEOJul 03Option Exercise7.1850,000359,000154,591Jul 03 08:11 PM
MORRISSEY MICHAELPresident and CEOJul 03Sale21.0334,721730,183119,870Jul 03 08:11 PM
SCANGOS GEORGE ADirectorJul 01Sale21.5840,000863,2001,168,031Jul 03 08:13 PM
Lamb PeterEVP, Scientific Strategy & CSOJun 19Option Exercise5.5117,40495,896134,601Jun 19 09:30 PM
Lamb PeterEVP, Scientific Strategy & CSOJun 18Option Exercise2.64100,000263,711217,197Jun 19 09:30 PM
Lamb PeterEVP, Scientific Strategy & CSOJun 18Sale20.67100,0002,067,000117,197Jun 19 09:30 PM
Lamb PeterEVP, Scientific Strategy & CSOJun 17Option Exercise5.38100,000538,259217,197Jun 19 09:30 PM
Lamb PeterEVP, Scientific Strategy & CSOJun 17Sale20.53117,4042,410,307117,197Jun 19 09:30 PM
Lamb PeterEVP, Scientific Strategy & CSOJun 13Option Exercise5.5627,596153,434144,793Jun 14 08:11 PM
Lamb PeterEVP, Scientific Strategy & CSOJun 13Sale20.0327,596552,748117,197Jun 14 08:11 PM
Haley Patrick J.Sr. Vice President, CommercialJun 10Sale20.231,00020,23088,453Jun 12 08:16 PM
SCANGOS GEORGE ADirectorJun 04Sale20.0015,000300,0001,208,031Jun 05 08:21 PM
SCANGOS GEORGE ADirectorJun 03Sale19.6125,000490,2501,223,031Jun 05 08:21 PM
MORRISSEY MICHAELPresident and CEOMay 29Option Exercise7.1814,591104,763104,591May 30 08:53 PM
SCANGOS GEORGE ADirectorMay 21Option Exercise4.5715,00068,5501,248,031May 22 08:52 PM
Haley Patrick J.Sr. Vice President, CommercialMay 10Sale19.581,00019,58089,453May 10 08:35 PM
MORRISSEY MICHAELPresident and CEOMay 08Option Exercise5.5642,000233,520132,000May 10 08:21 PM
MORRISSEY MICHAELPresident and CEOMay 08Sale20.1542,000846,30090,000May 10 08:21 PM
WILLSEY LANCEDirectorMay 08Sale20.3650,0001,018,000368,273May 10 08:20 PM
Senner Christopher J.EVP and CFOMay 03Sale20.7036,261750,603112,362May 03 08:55 PM
SCANGOS GEORGE ADirectorMay 02Sale20.0015,000300,0001,233,031May 03 08:52 PM
SCANGOS GEORGE ADirectorMay 01Sale19.7525,000493,7501,248,031May 03 08:52 PM
MORRISSEY MICHAELPresident and CEOApr 24Option Exercise5.5640,000222,400130,000Apr 26 08:14 PM
MORRISSEY MICHAELPresident and CEOApr 24Sale20.7540,000830,00090,000Apr 26 08:14 PM
MORRISSEY MICHAELPresident and CEOApr 10Option Exercise5.5640,000222,400130,000Apr 12 07:56 PM
Haley Patrick J.Sr. Vice President, CommercialApr 10Sale24.041,00024,04088,780Apr 12 07:59 PM
MORRISSEY MICHAELPresident and CEOApr 10Sale24.0640,000962,40090,000Apr 12 07:56 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOApr 03Option Exercise7.1863,109453,123379,622Apr 03 08:17 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOApr 03Sale25.0063,1091,577,725316,513Apr 03 08:17 PM
SCANGOS GEORGE ADirectorApr 03Sale25.035,000125,1501,273,031Apr 03 08:05 PM
Garber Alan MDirectorApr 01Option Exercise5.2530,000157,35076,329Apr 03 07:58 PM
Hessekiel JeffreyEVP and General CounselApr 01Option Exercise1.7020,00034,000253,820Apr 03 08:01 PM
WYSZOMIERSKI JACK LDirectorApr 01Option Exercise4.3926,250115,350128,031Apr 03 08:09 PM
WYSZOMIERSKI JACK LDirectorApr 01Sale23.977,822187,493120,209Apr 03 08:09 PM
SCANGOS GEORGE ADirectorApr 01Sale24.0240,000960,8001,278,031Apr 03 08:05 PM
Hessekiel JeffreyEVP and General CounselApr 01Sale24.0320,000480,600233,820Apr 03 08:01 PM
Garber Alan MDirectorApr 01Sale23.9930,000719,55061,329Apr 03 07:58 PM
POSTE GEORGEDirectorMar 29Option Exercise4.5715,00068,550106,335Mar 29 07:37 PM
POSTE GEORGEDirectorMar 29Sale23.893,86092,215102,475Mar 29 07:37 PM
MORRISSEY MICHAELPresident and CEOMar 27Option Exercise5.5640,000222,400130,000Mar 29 07:41 PM
MORRISSEY MICHAELPresident and CEOMar 27Sale23.3940,000935,60090,000Mar 29 07:41 PM
Haley Patrick J.Sr. Vice President, CommercialMar 26Option Exercise5.182,70013,98692,480Mar 27 08:31 PM
Haley Patrick J.Sr. Vice President, CommercialMar 26Sale23.472,70063,36989,780Mar 27 08:31 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOMar 25Option Exercise7.18100,000718,000416,513Mar 27 08:33 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOMar 25Sale23.14100,0002,314,000316,513Mar 27 08:33 PM
Haley Patrick J.Sr. Vice President, CommercialMar 14Option Exercise1.762,0003,52091,780Mar 15 08:10 PM
open in yahoo | open in reuters | open in google